CN Patent

CN115038443A — 包含alk2抑制剂和jak2抑制剂的组合疗法

Assigned to Incyte Corp · Expires 2022-09-09 · 4y expired

What this patent protects

本文提供了化合物、包含此类化合物的药物组合物以及使用此类化合物治疗与JAK2和/或ALK2相关的疾病或障碍的方法。

USPTO Abstract

本文提供了化合物、包含此类化合物的药物组合物以及使用此类化合物治疗与JAK2和/或ALK2相关的疾病或障碍的方法。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN115038443A
Jurisdiction: CN
Classification: —
Expires: 2022-09-09
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.